Genetic tests to detect cancer are feasible. But with researchers drowning in a sea of biomarkers and little financial incentive to get the tests on the shelves, the idea is floundering. Virginia Gewin reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Gewin, V. Missing the mark. Nature 449, 770–771 (2007). https://doi.org/10.1038/449770a
Published:
Issue Date:
DOI: https://doi.org/10.1038/449770a
